5:04 PM
 | 
Oct 11, 2018
 |  BC Innovations  |  Emerging Company Profile

Spinogenix’s Spine Craft

Spinogenix is rebuilding dendritic spines, cognition in neurodegeneration

Spinogenix Inc. is developing small molecules for cognitive impairment in neurodegenerative diseases that rebuilds dendritic spines to reverse, not just halt, synaptic loss.

CNS synapses that relay signals involved in memory and cognitive function are formed between the axon of one neuron and the dendritic spines of the next. Synaptic loss and dendritic spine retraction correlate with cognitive impairment across neurodegenerative diseases. Neuronal architecture depends on how actin filaments interact and align themselves with other actin filaments, and some actin arrangements can prohibit or permit the outgrowth of dendritic spines.

Spinogenix’s lead asset, SPG302, is a third-generation tetraethylene glycol derivative of benzothiazole aniline that it developed from prototype compounds in-licensed from University of California San Diego. SPG302 targets an undisclosed protein that regulates the interior architecture of neurons to rebuild retracted dendritic spines.

“We are disinhibiting...

Read the full 661 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >